The company reported 82% year-over-year revenue growth in Q2 2026 and targets over 100 instruments and $400,000 pull-through.
Alamar Biosciences projected 2026 revenue between $116M and $120M, reflecting continued business momentum. The company highlighted an 82% year-over-year revenue increase in Q2 2026, with consumable revenue comprising 53% of total revenue and rising.
In the prior year, Alamar had not disclosed a comparable revenue outlook, making this the first formal guidance for 2026. The company also set targets to expand its instrument base to over 100 and achieve pull-through exceeding $400,000.
Management attributed the growth to strong demand for its consumable products and operational execution during the quarter.